Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Merck KGaA Announces Phase III Trial Failure

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

German pharmaceutical company Merck KGaA announced in a press release that its Phase 3 trial of an experimental cancer  vaccine, formerly known as Stimuvax, has failed to meet its primary endpoints of the trial. Stimuvax, which Merck KGaA licensed from biotech company Oncothyreon (UNKNOWN: ONTY.DL  ) , did not show a statistically significant improvement in overall survival.

While the trials showed some progress, such as no new safety concerns arising, Merck said in the release that it will discuss the results with regulators and experts in the near future. The company plans to continue a clinical study of the drug in Asia, after the discussions.

Deutsche Bank analyst Holger Blum wasn't so optimistic  on the drug, saying, "Despite potential positive effects in subgroups, we consider the drug dead."

Shares of Oncothyreon fell sharply on the day, dropping more than 5%. Merck had a slightly better day, receiving a long-term credit rating upgrade  from Moody's, despite the failure of the clinical trial.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2164981, ~/Articles/ArticleHandler.aspx, 10/23/2016 2:19:23 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/10/2016 4:00 PM
ONTY.DL $1.06 Down -0.02 -1.85%
Oncothyreon CAPS Rating: ****